CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 11,999 enrolled
Drug / intervention
Zoster Vaccine, Live +1 morebiological
Likely dose
Zoster Vaccine, Live 0.65 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00550745
NCT00550745Phase 4Completed
CompareCT.gov

A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age

Merck Sharp & Dohme LLC·interventional·Posted Oct 30, 2007·Updated Apr 12, 2017

In Brief

A Phase 4 clinical trial evaluating Zoster Vaccine, Live and Comparator: placebo for Herpes Zoster. Completed, enrolled 11,999 participants.

Detailed Summary

The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2007
Enrollment StartSep 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.7 years ago

Interventions

Zoster Vaccine, Livebiological

single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.

Comparator: placebobiological

single 0.65 mL Placebo injection. 6 month treatment period.